Lilly Aims To Lower NME Cost To $800 Mil. Via Incremental Improvements
Executive Summary
Lilly is aiming for a 33% reduction in the cost of launching a new molecular entity by 2010 through incremental improvements in several stages of the drug developmental process
You may also be interested in...
First-Cycle Approvals May Rise For Second Consecutive Year – Parexel Report
First-cycle approvals by FDA's Center for Drug Evaluation & Research may continue to rise for a second consecutive year, according to Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2006/2007
Drugs With Better Sales Have Better Development Times, Study Finds
Drugs with strong sales were developed more quickly than drugs with weaker sales, according to an analysis published in the March/April issue of Health Affairs
Tri-Agency Oncology Biomarker Initiative Commences With PET Scan Study
Oncology biomarker qualification efforts jointly tackled by FDA, the National Cancer Institute and CMS will encompass prospective studies and ongoing clinical trials